Treatment of severe acute respiratory syndrome (SARS) in designated hospital: expenditure analysis and the impact of SARS on hospital economics_Chinese Journal of Evidence-Based Medicine

Authors：

SUN Xin ¹ , LI Youping ¹² , HUANG Ouning ³ , HE Yunfang ³ , SHEN Ji ⁴ , KUANG Pu ⁵

1. Key Lab of Transplant Engineering and Immunology （Ministry of Health）; West China Hospital; Sichuan University; Chengdu; 610041 2. Chinese Cochrane Center; Sichuan University 3. 410 Hospital; Guang Yuan; Sichuan Province4. Provincial Department of Health; Sichuan Province 5. West China School of Clinical Medicine; Sichuan University;

Corresponding author：

Keywords：

SARS; designated hospital; expenditure analysis

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Background 　410 Hospital, a hospital in an undeveloped city, identified the first three SARS cases in February, and three more cases in April in Sichuan province. After April 25, it was designated to treat the SARS cases.
Objectives 　This study aims to assess the expenditure for prevention and control of SARS in designated hospital and the impact of SARS on hospital management.
Methods 　With the perspective of SARS designated hospital, a retrospective study was designed. The measures for benefit was healing rate. Medical expenditures of SARS treatment was evaluated, total expenditare were included for assessment in SARS control and management in designated hospital. Sensitivity analysis was applied to explore the range of expenditures when hospital infection rate and healing rate varied.
Results 　All five SARS cases and six suspected cases were cured. The treatment expenditure for SARS confirmed and suspected cases were 7 866 and 4 273 RMB, and their medical expenditures were 14 983.86 and 5 494.92 RMB. Except the expenditure of supporting drugs, no statistical significance was identified in expenditures between confirmed and suspected cases. The total expenditure for designated hospital in control and management of SARS was 1.744 5 million RMB. After designation, the total income of the hospital decreased 33.45 percent compared that before designated. The hospital visits in out-patient and in-patient departments drop 43.62 and 47.33 percent.
Conclusions 　The expenditure of treatment of confirmed and suspected SARS cases were 14 983.86 and 5 490.92 RMB. After designation, the hospital would be great influenced in its management and income.

Citation： SUN Xin,LI Youping,HUANG Ouning,HE Yunfang,SHEN Ji,KUANG Pu. Treatment of severe acute respiratory syndrome (SARS) in designated hospital: expenditure analysis and the impact of SARS on hospital economics. Chinese Journal of Evidence-Based Medicine, 2003, 03(2): 135-141. doi: Copy

1.	［1］Jefferson T, Dernicheli V, Deeks J, Rivetti D Neuraminidase in hibitors for preventing and treating influenza in healthy adults CSR [M/CD] CL 2003 - 1.
2.	［2］Donald R. Husereau, B. Sc. Pharm M. Sc. 1 Bruce Brady , M. A ,M. Sc. 1 Allison McGeer MD, FRCPC2Oseltamivir for the treeatment of suspected influenza a clinical and economic assessmeont[R]. CCOHTA Issue 21 2001.
3.	［3］Burls A, Clark W, Stewart T, Preston C, Bryan S, Jefferson T,et al. Zanamivir [or the treatment of influenza in adults: a system atic review and economie evaluation. HTA 2002; 6 (9). NHS R&D HTA Programme.
4.	［4］Full Guidance on the the use of zanamivir, oseltamivir and amantadine for the treatment of influenza Tecbnology Appraisal Guidance No. 58 [S] NHS February 2003.
5.	［5］Do neuraminidase inhibitors prevent influenza [R] CCOHTA. Issue 27 November 2001.
6.	［6］Treating influenza by medication - Zanamivir SBU Alert May 22,2001.
7.	［7］Gideon Koren, Susan King, Sandra Knowles, Elizabeth PhillipsRibavirin in the treatment of SARS: A new trick for auold drug [J]? JAMC 13 MAI 2003; 168 (10).
8.	［8］Jefferson TO, Tyrrell D Antivirals for the Common Cold CSR [M/CD]CL 2003- 1.
9.	［9］Randolph AG, Wang EEL Ribavirin for respiratory syncytial virns infection of the lower respiratory tract CSR [ M/CD ] CL 2003-1.

1. ［1］Jefferson T, Dernicheli V, Deeks J, Rivetti D Neuraminidase in hibitors for preventing and treating influenza in healthy adults CSR [M/CD] CL 2003 - 1.
2. ［2］Donald R. Husereau, B. Sc. Pharm M. Sc. 1 Bruce Brady , M. A ,M. Sc. 1 Allison McGeer MD, FRCPC2Oseltamivir for the treeatment of suspected influenza a clinical and economic assessmeont[R]. CCOHTA Issue 21 2001.
3. ［3］Burls A, Clark W, Stewart T, Preston C, Bryan S, Jefferson T,et al. Zanamivir [or the treatment of influenza in adults: a system atic review and economie evaluation. HTA 2002; 6 (9). NHS R&D HTA Programme.
4. ［4］Full Guidance on the the use of zanamivir, oseltamivir and amantadine for the treatment of influenza Tecbnology Appraisal Guidance No. 58 [S] NHS February 2003.
5. ［5］Do neuraminidase inhibitors prevent influenza [R] CCOHTA. Issue 27 November 2001.
6. ［6］Treating influenza by medication - Zanamivir SBU Alert May 22,2001.
7. ［7］Gideon Koren, Susan King, Sandra Knowles, Elizabeth PhillipsRibavirin in the treatment of SARS: A new trick for auold drug [J]? JAMC 13 MAI 2003; 168 (10).
8. ［8］Jefferson TO, Tyrrell D Antivirals for the Common Cold CSR [M/CD]CL 2003- 1.
9. ［9］Randolph AG, Wang EEL Ribavirin for respiratory syncytial virns infection of the lower respiratory tract CSR [ M/CD ] CL 2003-1.

Chinese Journal of Evidence-Based Medicine

Treatment of severe acute respiratory syndrome (SARS) in designated hospital: expenditure analysis and the impact of SARS on hospital economics

Abstract Full text Figures/Tables Video References Cited by

Format

Content